The company has rededicated itself to a fully blood-based test pipeline, with its next assays focused on women's health, including endometriosis and ovarian, uterine, and cervical cancers.
MDNA said the arrangement will help it to quickly build a user base and collect post-market data to demonstrate the test's clinical utility.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
The new partnership will make data from more than 9 million anonymized veterans' medical records available for research.
Roughly one-third of castration-resistant prostate cancer cases appear to involve rearrangements affecting the androgen receptor gene.
The company has advanced sequencing-based copy number analyses to assess genomic instablity in CTCs, and used that to develop a method to predict response to PARP inhibitors based on the phenotype, or appearance, of genomically unstable CTCs.
The projects focus on early treatment of prostate cancer and cataloguing mutations in difficult-to-diagnose diseases, among other things.
Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The firm said that it delivered more than 29,990 test results in the third quarter of 2016 compared to 27,820 results delivered in Q3 2015.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.